Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan
NEW YORK and LEAMINGTON, Ontario, March 16, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray…
Year: 2023
Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan
NEW YORK and LEAMINGTON, Ontario, March 16, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray…
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024…
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024…
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps…
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps…
MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30
Management to host investor conference call and webcast at 4:30pm ET on that day PHOENIX,…
MedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30
Management to host investor conference call and webcast at 4:30pm ET on that day PHOENIX,…
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
CHATHAM, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
CHATHAM, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533…
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533…
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET SAN JOSE,…
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET SAN JOSE,…
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Announced SC291 IND clearance with goal to report initial clinical data this year Expect to…
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Announced SC291 IND clearance with goal to report initial clinical data this year Expect to…